EUVIMEDEUVIMED entdecken
Open Access

Real-world analysis of the use of lenvatinib in differentiated thyroid cancers

Zoya Peelay, Deevyashali Parekh, Vijay M Patil, Vanita Noronha, Nandini Menon, Kumar Prabhash

ecancermedicalscience · 30.01.2023 · 17

DOI: 10.3332/ecancer.2023.1500 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ecancermedicalscience, online erschienen am 30.01.2023. Verfasst von Zoya Peelay und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tata Memorial Hospital, HBNI, Parel, Mumbai 400012, India. Die Arbeit wurde bisher 9-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Lenvatinib is one of the approved treatments for radioiodine-refractory differentiated thyroid cancers. However, there is very limited data from India on real-world efficacy and adverse events of Lenvatinib and hence this analysis was performed.

Methods

This was a retrospective analysis in which patients of radioiodine-refractory differentiated thyroid cancer as per the SELECT study criteria, who received lenvatinib, were selected for the study over the last 4 years. The baseline demographic characteristics, adverse events of lenvatinib, the date of progression and the date of overall survival (OS) were extracted from the electronic medical records of Tata Memorial Hospital. SPSS version 20 was used for analysis.

Results

The median starting dose of lenvatinib was 20 mg. Fifteen events for progression had occurred and the median progression-free survival (PFS) was 12.2 months [95% CI: 4.4-not available (NA)]. The events for OS analysis were 12. The median OS was 35.3 months (95% CI: 11.4-NA). There was no impact on starting dose on PFS or OS.

Conclusion

The real-world data of Lenvatinib suggest a lot of variability in the starting dose. In spite of this variability, the response rates and OS are similar to that noted in pivotal study. This suggests a case for need for more studies evaluating lower doses of Lenvatinib.

Schlagwörter

Stichwörter der Autor:innen

dedifferentiatedfollicularlenvatinibpapillaryradioiodine refractorythyroid cancer

Autor:innen und Institutionen

  • Department of Medical Oncology, Tata Memorial Hospital, HBNI, Parel, Mumbai 400012, India.

Zitieren

APA

Peelay, Z., Parekh, D., Patil, V. M., Noronha, V., Menon, N., & Prabhash, K. (2023). Real-world analysis of the use of lenvatinib in differentiated thyroid cancers. ecancermedicalscience, 17. https://doi.org/10.3332/ecancer.2023.1500

Vancouver

Peelay Z, Parekh D, Patil VM, Noronha V, Menon N, Prabhash K. Real-world analysis of the use of lenvatinib in differentiated thyroid cancers. ecancermedicalscience. 2023;17. doi:10.3332/ecancer.2023.1500

BibTeX
@article{Peelay2023,
  author = {Peelay, Zoya and Parekh, Deevyashali and Patil, Vijay M and Noronha, Vanita and Menon, Nandini and Prabhash, Kumar},
  title = {Real-world analysis of the use of lenvatinib in differentiated thyroid cancers},
  journal = {ecancermedicalscience},
  year = {2023},
  volume = {17},
  doi = {10.3332/ecancer.2023.1500}
}
Kostenlos starten →